DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Annual Results/Annual Report
Bad Neustadt a. d. Saale | 24 March 2022 RHÖN-KLINIKUM AG looks back on successful financial year 2021 - Financial year 2021 again gripped by COVID-19 pandemic - Targets met - consolidated profit and revenues increase - Letter of Intent for enhancing separate accounting agreement signed - CEO Höftberger: Reform of healthcare planning and financing in German hospital market indispensible
In financial year 2021, revenues grew by 3.1 per cent to reach 1.4 billion. EBITDA gained 26.1 per cent to reach 101.2 million, well above the previous year's level. The trend in revenues and EBITDA was thus in line with the forecast. Consolidated profit increased by roughly 27.7 million euros to reach 30.2 million euros. At the five hospital sites RHÖN-KLINIKUM Campus Bad Neustadt, Klinikum Frankfurt (Oder), the Giessen and Marburg University Hospitals (UKGM) and Zentralklinik Bad Berka, as well as at our medical care centres (MVZs), we treated a total of 845,642 patients, a gain of 4.6 per cent compared with the previous year. As at 31 December 2021, the Company employed 18,227 persons. We continue to see some of the most pressing tasks of the Company in the following areas of action: Letter of Intent for enhancing separate accounting agreement signed For the period of 2022 to 2031 the Federal State of Hesse expressed the prospect of funding investment costs in the total amount of nearly half a billion euros. For the ten-year period of the agreement UKGM in return is expected, among other things, to guarantee that it will refrain from redundancies and from outsourcing business units. Provided the parties succeed in agreeing the final terms, a binding contractual agreement is expected to be concluded in the second quarter of 2022. Dr. Christian Höftberger, Chairman of the Board of Management of RHÖN-KLINIKUM AG, stated: "We were always open to a pragmatic solution if it effectively helps UKGM. That's why we are prepared to make concessions. UKGM is entitled to reasonable investment funding in line with the dual financing principle enshrined in German hospital financing legislation, under which hospitals' operating costs are borne by the health insurance funds and their investment costs by the federal states. Especially now in times of political and economic uncertainty amid a quickly changing healthcare system, the most important task of all stakeholders is to support UKGM in fulfilling its duties in research, teaching and healthcare provision." Reforms in healthcare system indispensible As the operator of several systemically relevant hospitals, RHÖN-KLINIKUM AG also considers it essential to call on federal politicians to undertake an all-encompassing reform of healthcare planning and funding. The rules currently in force are characterised among other things by obstacles and barriers between the outpatient and inpatient sectors which are now outdated and obsolete. These barriers must be overcome - also with the help of digital offerings. Moreover, they fail to adequately reflect the cost structures of the intermediate- and maximum-care providers and in particular university medicine in the system of diagnosis-related groups (DRGs). The reform announced by the traffic light coalition partners must be clarified promptly with the involvement of representatives of service providers and then implemented without any further delays. In light of the imponderables due to the pandemic but also the challenging financial situation, RHÖN-KLINIKUM AG is urgently calling for hospitals to be provided with tangible relief from bureaucratic red tape and better financial support through investment grants from the federal states. "In Germany we have an outstanding hospital system. To make sure it stays that way, the federal states must better fulfil their statutory responsibility to assume investment costs - in the interests of healthcare workers and patients alike" Höftberger said. Outlook for 2022 For the current financial year, we expect revenues of 1.4 billion euros within a range of plus or minus 5 per cent. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between 92 million euros and 102 million euros. The outlook is subject to considerable uncertainties in connection with the further course of the COVID-19 pandemic and any regulatory measures impacting our remuneration structure in 2022. ----------------------------------------------------- RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 846,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs around 18,200 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
RHÖN-KLINIKUM AG | Schlossplatz 1 | 97616 Bad Neustadt a. d. Saale | Germany
24.03.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | RHÖN-KLINIKUM Aktiengesellschaft |
Salzburger Leite 1 | |
97616 Bad Neustadt a.d.Saale | |
Germany | |
Phone: | +49 (0)9771 - 65-0 |
Fax: | +49 (0)9771 - 97 467 |
E-mail: | rka@rhoen-klinikum-ag.com |
Internet: | www.rhoen-klinikum-ag.com |
ISIN: | DE0007042301 |
WKN: | 704230 |
Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: | 1310433 |
End of News | DGAP News Service |
|
1310433 24.03.2022
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.